Showing results (81-90 of 337) with videos related to
Sort By:
Pageof 34
Regulatory Peptides|April 29, 1993
Neurohypophyseal peptides and psychiatric diseasesJ J Legros, M Ansseau, M Timsit-BerthierRevue Medicale De Liege|August 6, 2010
[Recovering from depression: a matter of objective and determination]W Pitchot, G Scantamburlo, E Pinto, et al.Acta Psychiatrica Belgica|September 1, 1980
Biochemical and neuroendocrine approaches to a malignant syndrome of neurolepticsM Ansseau, S Diricq, T Grisar, et al.Acta Psychiatrica Belgica|September 1, 1983
Pilot study of a specific serotonergic antagonist, pirenperone, in the treatment of anxiety disordersM Ansseau, A Doumont, D Thiry, et al.Revue Medicale De Liege|August 2, 2008
[The electroconvulsive therapy in 2008]S Servais, M Ansseau, G Mikolajczak, et al.Journal of Psychopharmacology (Oxford, England)|December 31, 2002
Venlafaxine: the relationship between dose, plasma concentration and clinical response in depressive patientsC Charlier, E Pinto, M Ansseau, et al.Revue Medicale De Liege|March 13, 2010
[Inappropriate antidiuretic hormone secretion induced by sodium valproate]E Bève, E Beck, E Pinto, et al.Journal of Clinical Psychopharmacology|July 31, 2001
Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic featuresJ D Guelfi, M Ansseau, L Timmerman, et al.International Clinical Psychopharmacology|January 1, 1990
Pooling two controlled comparisons of milnacipran (F2207) and amitriptyline in endogenous inpatients. A new approach in dose ranging studiesR von Frenckell, M Ansseau, C Serre, et al.Neuroscience and Biobehavioral Reviews|June 6, 2003
Alcohol and withdrawal: from animal research to clinical issuesPh De Witte, E Pinto, M Ansseau, et al.Pageof 34